NEW YORK, May 16, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Global Bioinformatics Industry

http://www.reportlinker.com/p092468/Global-Bioinformatics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

This report analyzes the worldwide markets for Bioinformatics in US$ Million by following Product Segments: Software, Hardware, and Biocontent. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 206 companies including many key and niche players such as 3rd Millennium, Inc., Accelrys, Inc., Affymetrix, Inc., Agilent Technologies, Celera Group, Gene Logic, Geneva Bioinformatics S.A., IBM Life Sciences, ID Business Solutions Ltd., Instem Scientific Limited, Life Technologies Corporation, Kinexus Bioinformatics Corporation, and Nonlinear Dynamics Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

More:
Global Bioinformatics Industry

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/xwqrkw/indian_bioinformat) has announced the addition of the “Indian Bioinformatics Market Forecast to 2015″ report to their offering.

Bioinformatics is one of the fastest emerging interdisciplinary research areas, which may be defined as an interface between biological and computational sciences’. Most of the Bioinformatics work can be described as analyzing biological data, although a growing number of projects deal with the organization of biological information. Though the US remains the largest market in the world, Asia-Pacific countries (particularly India and China) are witnessing the fastest growth and are anticipated to emerge as the dominating forces in the future.

The Indian bioinformatics market, which is the smallest of biotech industry segments constituting barely 2% of the market share in overall revenue, grew by 11.5% in FY 2010-11 to reach US$ 58 Million. The market is backed by factors, such as tracking of discovery activities, data analysis, and pharmaceutical research. As global players augment drug discovery and research activities, the outsourcing of bioinformatics related work will also strengthen in the same proportion.

The report Indian Bioinformatics Market Forecast to 2015 has depicted a true picture of Indian bioinformatics market, its current and future position in the biotech industry and key drivers and restraints. An in-depth insight into the advantages offered by India as a country in bioinformatics has also been provided here. In such a way, clients can attain an understanding of workforce, educational structure, and government support with respect to bioinformatics in India.

The report is an outcome of an extensive research and prudent analysis of Indian bioinformatics market that seeks to deliver reliable statistics and important information associated with key aspects/areas. While forecasting the market values in key parts of the report, a valuable emphasis has been given to the usage of effective methods and techniques. The report also provides a brief description of market players actively supporting the industry developments.

Companies Mentioned

– Ocimum Biosolutions Ltd.

– CLC Bio India

– Siri Technologies

More here:
Research and Markets: Indian Bioinformatics Market Forecast to 2015

A team of bioinformatics researchers at Illumina Cambridge in the UK have developed a new compression algorithm for next-gen sequencing data that improves upon the old compression standby Burrows-Wheeler transform, or BWT, algorithm. The 18-year-old BWT serves as the basis for numerous compression and data indexing methods. However, because of its design, the technique cannot be applied successfully to large datasets typically produced by large genome sequencing runs.

The team, led by Illumina’s Anthony Cox, describe a novel algorithm that can allow the BWT of genome data to be analyzed using only “moderate” hardware, i.e. a workstation or a small cluster.

With 45x coverage of human genome sequence data that takes up roughly 135.3 GB of space, their technique can squash that data down to 8.2 GB. This is more than four times smaller than what can be achieved using a standard BWT-based compressor, such as the bzip2 format.

In addition to saving space and therefore money, the Illumina team’s approach can help facilitate the contraction of compressed full text indexes on large sequence collections.

See the original post:
Novel Algorithm Teaches Old Dog New Compression Tricks

Trovagene has named Carlo Croce to serve on its scientific advisory board. Croce is director of the Human Cancer Genetics Program and the Genetics Institute at The Ohio State University, and he is John W. Wolfe Chair in Human Cancer Genetics.

Population Genetics has named Alan Schafer as its new CEO. Schafer is an adjunct professor at Imperial College London Business School and was previously the Wellcome Trust’s director of science funding. Before that he served as global vice president of technology development at GlaxoSmithKline and co-founded Hexagen, a functional genomics company that was acquired by Incyte.

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

See the article here:
UK's BBSRC Issues Call for Nearly $10M in Bioinformatics Grants

Here is the original post:
Updated Tutorials on UCSC Genome Browser Now Available

DUBLIN–(BUSINESS WIRE)–

Dublin – Research and Markets (http://www.researchandmarkets.com/research/t2qm96/computational_appr) has announced the addition of John Wiley and Sons Ltd’s new book “Computational Approaches in Cheminformatics and Bioinformatics” to their offering.

A breakthrough guide employing knowledge that unites cheminformatics and bioinformatics as innovation for the future

Bridging the gap between cheminformatics and bioinformatics for the first time, Computational Approaches in Cheminformatics and Bioinformatics provides insight on how to blend these two sciences for progressive research benefits. It describes the development and evolution of these fields, how chemical information may be used for biological relations and vice versa, the implications of these new connections, and foreseeable developments in the future.

Using algorithms and domains as workflow tools, this revolutionary text drives bioinformaticians to consider chemical structure, and similarly, encourages cheminformaticians to consider large biological systems such as protein targets and networks.

Computational Approaches in Cheminformatics and Bioinformatics covers:

– Data sources available for modelling and prediction purposes

– Developments of conventional Quantitative Structure-Activity Relationships (QSAR)

– Computational tools for manipulating chemical and biological data

– Novel ways of probing the interactions between small molecules and proteins

Read the original:
Research and Markets: Computational Approaches in Cheminformatics and Bioinformatics

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm’s North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children’s Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

See the rest here:
IP Update: Metabolon, U of Tennessee, New York University Among Recent Bioinformatics Patent Winners

HAYWARD, CA–(Marketwire -04/27/12)- An interdisciplinary team of microbiologists, plant bioengineers and bioinformatics experts of the Leibniz Institute DSMZ – German Collection of Microorganisms and Cell Cultures in Braunschweig has developed an application-oriented software package for the analysis of Biolog high-throughput phenotypic data. The ‘opm’ (OmniLog Phenotype MicroArray) package, which is based on the free software environment R, allows comprehensive statistical analyses on quantitative data of energy production curves and a better graphic presentation. The new software can provide a valuable contribution toward the greater understanding of physiological interactions in the metabolism of diverse cells, from microorganisms to cancer cells. The initial findings are published in the current issue of the scientific journal PLoS ONE.

Which properties do bacteria, fungi, yeasts or even cancer cell lines have? This question is commonly just as important in basic research as in applied biology. The determination of these properties in the laboratory is often laborious and time consuming. Automatic high-throughput screening such as the Phenotype MicroArray System of the company Biolog, Inc. provides the solution. Here the response of bacteria, yeasts, fungi and animal cells can be tested in parallel for nearly 2,000 physiological assays.

“With the use of a redox dye that forms a violet pigment, up to 96 chemical substances are tested on a single microtitre plate at the same time. One can test whether these substances provide an energy source for microorganisms or cell lines, or have possible antibiotic effects,” says microbiologist Dr. Johannes Sikorski. “Changes in the intensity of the pigment formation is measured at frequent intervals of 15 minutes. As a result, highly informative so-called ‘respiration kinetics’ appear as kinetic graphs, similar to a typical growth curve of bacteria. By measuring over the course of four days, just under 2,000 curves, each with around 380 measured values, can be recorded in a single experiment. Valuable biological information can be derived from the curve, such as the inception, strength and intensity of a physiological reaction.”

In order to mine this data, an interdisciplinary team of microbiologists, plant bioengineers and bioinformatics experts of the Leibniz Institute DSMZ has developed a novel software package based on the free software environment R (www.r-project.org). “Until now the analysis software from the manufacturer Biolog was only partially suitable to graphical and statistical evaluation of this wealth of high dimensional data,” explains Dr. Markus Gker, an expert in bioinformatics who was responsible for programming the ‘opm’ package. “Until now most users have analysed data based upon whether a reaction takes place or not. As a result, much valuable data, and therefore significant information, was discarded.”

“The new ‘opm’ package allows for a comprehensive evaluation of curve kinetics with numerous high-resolution forms of graphical analyses. Through the so-called ‘bootstrapping technique’ one can also test the extent to which individual curves vary significantly from one another. The real strengths of ‘opm’ lie, however, in that we have enabled all desired analyses for all parts of the comprehensive data record,” says Dr. Markus Gker.

“The user can add metadata on the organisms tested or annotate the experimental conditions applied virtually without restriction. Diverse search and selection functions for raw data, curve parameters and metadata allow it to work on specific questions on each data record,” explains Lea Vaas, plant bioengineer. “Therefore, with the ‘opm’ software package, there will be diverse opportunities for innovative test design: tests on metabolism and gene function of microorganisms, such as gene defects coding for regulatory enzymes or even the reaction of cancer cells to anti-cancer agents. All of these can now be analysed at a substantially more detailed level with the OmniLog Phenotype MicroArray system.”

Barry Bochner, Ph.D., CEO & CSO of the manufacturer, Biolog, is pleased about the successful cooperation with the Leibniz Institute DSMZ. He explains that: “The newly developed ‘opm’ package from the researchers of the Leibniz Institute DSMZ can clearly expand and improve the application parameters and significance of Biolog tests and thus offer our users decisive advantages in their research.”

Further background information on the ‘opm’ software and free download can be found at http://www.dsmz.de/research/microorganisms/projects/analysis-of-omnilog-phenotype-microarray-data.html

About the Leibniz Institute DSMZ:The Leibniz Institute DSMZ – German Collection of Microorganisms and Cell Cultures is an institution of the Leibniz Corporation, and with its comprehensive scientific services and a wide spectrum of biological materials, it has become a worldwide partner for research and industry for decades. As one of the largest biological resource centres of its kind, the DSMZ has been certified to the quality standard ISO 9001:2008 valid worldwide. Alongside the scientific service, the collection-related research forms the second pillar of DSMZ. The collection based in Braunschweig has existed for 42 years and accommodates more than 30,000 cultures and biomaterials. The DSMZ is the most diverse collection worldwide: alongside fungi, yeasts, bacteria and archaea, human and animal cell cultures, as well as plant viruses and plant cell cultures are explored and archived there as well.

About Biolog:Biolog is a privately held company based in Hayward, CA, that continues to lead in the development of powerful new cell analysis tools for solving critical problems in biological, pharmaceutical, and biotechnological research and development. It is the world leader in phenotypic cell profiling. Biolog’s products allow scientists to study the growth properties and culture condition responses of bacterial, fungal, and even human cells. As such it is becoming a core technology for many cellular studies. Further information can be obtained at Biolog’s website, www.biolog.com.

Read more here:
Researchers at DSMZ Develop Innovative Software for Biolog Phenotypic Analyses to Improve Our Understanding of the …

More here:
DNA2.0 Introduces Custom Bioinformatics Services

Joel Dudley, director of informatics and co-founder of one-year-old NuMedii, Inc

The use of bioinformatics to find new applications for existing drugs is opening doors to treatments that are cheaper and easier to bring to market, and with that, a host of business opportunities.

Between 30-40 percent of drugs or biologics that were approved or launched for the first time in the US in 2007-2009 were either drugs repositioned for new indications, reformulations or new combinations of existing drugs, according to a Spring 2011 article in Drug Discovery World. So its no surprise that drug discovery informatics was one of the better-attended discussions at this weeks Bio-IT World Conference, held at Bostons World Trade Center in the Seaport District. About 80 attendees on Thursday afternoon saw first-hand some of the ways companies as big as GlaxoSmithKline and as small as year-old startups are applying computational power to find disease relationships and drug relationships that have not yet been explored.

Pankaj Agarwal, director of computational biology and bioinformatics at GlaxoSmithKline, presented methods for drug repositioning, such as the Genome Wide Association Study (GWAS), of what genes are associated with what diseases. Comparing the database to the industry pipeline of drugs, Agarwal found 155 of the genes targeted by drugs were being actively pursued, while 92 were not. That means there are a lot of opportunities, he said.

I think there is a lot more work that can be done in that regard, he said.

Challenges of drug repositioning include translating data with different categories, and sometimes even finding a usable source of data. Agarwal cited one recent study which text-mined data on drug side effects from drug labels – there is no central repository of side effects, he said – in order to match up drugs with similar side effects as an indication that they might be usable for similar diseases.

Another method involves disease signatures. Using disease relationships developed from genetic pathways, type 2 diabetes, for example has been show to be related to Alzheimers disease. Alzheimers is sometimes even referred to as type 3 diabetes, said Agarwal. But again, he said, the part that still remains a challenge for us is… where do you get these disease signatures?

One of the richest sources of data is Medicare hospitalization data from 32 million patients. Agarwal proposes significant relationships could be found by putting not only diseases, but drugs, into the network.

The challenge, he said, is not the magnitude of the data but the ability to ask answerable and testable questions.

We should always go back and figure out what the right question is, and not what the right data is.

Originally posted here:
Bioinformatics opens doors to new markets

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm’s North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children’s Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

View original post here:
Funding Update: NSF Bioinformatics Grants Awarded March 20 — April 18, 2012

More here:
BioInformatics LLC New Market Report – Life Science Sales Reps: Guide to Best Practices in 2012

Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2.

Nat Methods. 2012 Mar 4;9(4):357-9.

Craigen WJ, Graham BH, et al. An integrated approach for classifying mitochondrial DNA variants: one clinical diagnostic laboratory’s experience.

Genet Med. 2012 Mar 8. [Epub ahead of print].

Bicak M, Booth T, et al. Cloud BioLinux: pre-configured and on-demand bioinformatics computing for the genomics community.

BMC Bioinformatics. 2012 Mar 19;13(1):42.

Hamilton CM, Junkins HA, et al. Using PhenX measures to identify opportunities for cross-study analysis.

Hum Mutat. 2012 Mar 13. [Epub ahead of print].

Burriesci MS, Lehnert EM, Pringle JR. Fulcrum: condensing redundant reads from high-throughput sequencing studies.

Bioinformatics. 2012 Mar 13. [Epub ahead of print]

See more here:
In Print: March's Bioinformatics Papers of Note

By Uduak Grace Thomas

Novocraft, a Malaysian-based bioinformatics software vendor, is hoping that the improved accuracy of its alignment software, Novoalign, will reel in new customers in the next-generation sequence data analysis space.

Novoalign is a short-read alignment software program that lets users align single-end and paired-end reads from Illumina and Roche 454 sequencers.

Features include an alignment mode for bisulfite sequencing data; base quality calibration during the alignment process to improve sensitivity and specificity; multithreading capabilities; and adapter trimming for paired-end and short RNA reads.

Zayed Albertyn, Novocraft’s bioinformatics director, told BioInform this week that the software, which is based on the Needleman-Wunsch algorithm, is more sensitive when it comes to selecting correct alignments for reads and identifying false positives than some well-known open source tools like the Burrows-Wheeler Aligner and Bowtie, which he considers the biggest threat to his firm’s business.

Some recent independent publications support Albertyn’s claims. For example, researchers from India’s Ganit Labs and Strand Life Sciences published a PLoS One paper in January that compared the abilities of several aligners including Novoalign, Bowtie, and Stampy.

According to the paper, Novoalign and Stampy were able to “maintain a consistently high-quality score across different variant callers” when the researchers looked at the average base quality score of variants.

Furthermore, they wrote, Novoalign produced “equally good variant quality no matter which downstream variant caller is used” a feat that they attributed to “a post-alignment base quality recalibration method” that Novoalign uses. This is compared to Stampy, which “yielded good quality scores for all variant callers, albeit with varying frequency,” although it also uses a post alignment base-recalibration approach.

A separate study published in Bioinformatics last year by researchers affiliated with the Max Planck Institute for Molecular Genetics looked at how MAQ, RazerS, Bowtie, BWA, and Novoalign aligned simulated datasets containing insertions and deletions.

Among other results, the researchers found that BWA was only able to map about 80 percent of reads from regions without indels, compared to 98 percent for Novoalign and RazerS. Of the indel-free mapped reads, Novoalign and BWA were able to map about 99 percent of reads to their correct coordinates compared to about 95 percent by RazerS.

Read the original:
Novocraft Touts Sequence Alignment Software's Accuracy as Key Differentiator in NGS Marketplace

By Matthew Dublin

BGI has announced a partnership with the National Supercomputing Center in Tianjin home of currently the world’s second most powerful supercomputer, the Tianhe -1A in order to take advantage of supercomputing technology to accelerate genomics research.

The joint venture will be known as the Tianhe-BGI Bioinformatics and Computing Joint Laboratory. To kick off the new collaboration, investigators from the two organizations will begin work on a new bioinformatics analysis pipeline for genomics data that will utilize the power of the Tianhe-1A supercomputer.

The Tianhe-1A supercomputer came online in October of 2012 and runs at a peak performance of roughly 2.57 petaflops per second. The system is equipped with 14,336 Xeon X5670 processors, 7,168 Nvidia Tesla M2050 general purpose GPUs, 2,048 FeiTeng 1000 SPARC-based processors.

In the next step, we will establish a comprehensive bioinformatics & computing platform based on Tianhe-1A. It will focus on the research and development of the high-performance software with higher efficiency, including standard analysis software, the analytical pipeline and tools for enormous data, among others. says Guangming Liu, Director of CSCC-TJ. We hope this new laboratory could greatly promote the applications of genomic technologies in agriculture, drug discovery and human health in Binhai New Area, and make more contributions to the society.

Read more from the original source:
BGI Establishes HPC Center for Bioinformatics

Dublin – Research and Markets (http://www.researchandmarkets.com/research/a9674d89/brand_performance) has announced the addition of the “Brand Performance in the Life Science Industry” report to their offering.

As the premier market research firm in the life science industry, few companies are as qualified as BioInformatics LLC to take on the task of determining the top supplier companies in 29 product and service categories. Over 6,000 life scientists from BioInformatics LLC’s online panel, The Science Advisory Board, participated in the nomination and voting process for the 2011 Life Science Industry Awards.

The awards were announced and summary results released on November 15, 2011. But going beyond the summary of results, life science suppliers will want to put these key findings into action. Therefore, in addition to calculating the popular vote, the data collected was analyzed by BioInformatics LLC to yield findings that life science suppliers can use.

Titled Brand Performance in the Life Science Industry, this deep dive into the results of the Life Science Industry Awards market study will enable life science suppliers to assess their own rankings in the industry, benchmark their performance against the competition and gain insight as to brand awareness, market position and overall satisfaction with products and supplier attributes.

Key Topics Covered:

Section 1: Presentation of Key Findings

Competing in a time of uncertainty

Consumables Categories

Instrumentation Categories

Research and Technology

Go here to see the original:
Research and Markets: Brand Performance in the Life Science Industry – Life Science Industry Awards Announced in …

CAMBRIDGE, Massachusetts, March 27, 2012 /PRNewswire/ —

IntelligentMDx (IMDx), a molecular diagnostic company that uses a proprietary bioinformatics platform that accelerates the development of PCR-based diagnostic testing solutions, will be presenting three posters at the 22nd annual European Congress of Clinical Microbiology and Infectious Diseases Meeting (ECCMID). The ECCMID meeting on March 31 – April 3, 2012 in London, UK, attracts more than 7,000 participants with expertise in infectious disease areas, including emerging infections, diagnosis, prevention, and treatment.

IMDx has designed, developed, and manufactured two CE-marked assays in the past year under a multi-year distribution agreement with Abbott. One CE-marked assay provides rapid and sensitive detection of toxigenic Clostridium difficile, while the second CE-marked assay provides for the detection of Vancomycin-resistant Enterococci. A third assay will be CE-marked later this year for the detection of Group B streptococcus. All three assays have been designed and validated to run on the Abbott m2000(TM) system, for fully automated, high-throughput diagnosis of these infectious diseases. The IMDx pipeline includes assays for detection of Herpes Simplex Virus 1 and 2, Influenza A/B and RSV, Epstein-Barr virus, BK virus, and additional assays targeting oncology, human genetics and companion diagnostics.

The three posters presented by Dr. Heinz Reiske, Manager of Research and Development at IMDx, will detail the technology used to develop the IMDx assays and present performance characteristics for each assay.

To view IMDx Posters at ECCMID, please visit:

* These products are intended for CE-marking and are not available for sale in the United States.

About IMDx

Based in Cambridge, MA, IMDx (http://www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDxs expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDxs proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.

Contact: Renda Hawwa, +1-617-871-6405

IntelligentMDx

See the article here:
IntelligentMDx to Present Development of Two CE-Marked Assays at 22nd Annual European Congress of Clinical …

REDWOOD CITY, Calif.–(BUSINESS WIRE)–

Natera, formerly known as Gene Security Network, today announced that data from studies of the companys bioinformatics Parental Support technology will be presented during the American College of Medical Genetics 2012 Annual Clinical Genetics Meeting at the Charlotte Convention Center in Charlotte, North Carolina.

Matthew Rabinowitz, Ph.D., CEO of Natera, will deliver an oral presentation, abstract 59, titled First Trimester Non-invasive Detection of Fetal Aneuploidy 13, 18, 21, and X by Targeted Sequencing. The session will begin at 3:45 p.m. EDT on Friday, March 30. Dr. Rabinowitz will discuss how Nateras core technology allows for early and accurate screening of fetal aneuploidy 13, 18, 21 and X.

During the same session, Ruth Lathi, M.D., Director of the Recurrent Pregnancy Loss Program at Stanford University , will deliver an oral presentation, abstract 58, titled Informatics-based Molecular Karyotyping of Products of Conception (POC) with Maternal Cell Contamination (MCC) Detection: Report on 1,222 Consecutive Analyses.

In addition, Brynn Levy, Ph.D. Director of Clinical Cytogenetics at Columbia University, will present during the OBGYN Geneticists Meeting on Wednesday, March 28. His presentation, titled Non-invasive Prenatal Diagnosis Beyond Down Syndrome: The PreNATUS Trial, will describe the ongoing, NIH-funded clinical investigation of Nateras non-invasive prenatal diagnostic test.

About Natera

Natera is a genetic testing company that has developed a proprietary bioinformatics technology (Parental Support) to deliver accurate and comprehensive high throughput testing for reproductive indications from tiny quantities of DNA as small as that from a single cell. Natera operates a CLIA laboratory in Redwood City, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include preimplantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an IVF cycle in order to select embryos with the highest probability of becoming healthy children; products of conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause; and non-invasive prenatal testing to determine paternity or detect genetic disease by analyzing fragments of fetal DNA in a pregnant mothers blood drawn in the first trimester. Non-invasive testing for paternity is currently available worldwide. Natera’s clinical trial for non-invasive detection of chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. For more information, visit www.natera.com.

Excerpt from:
Natera Announces Presentations During the American College of Medical Genetics 2012 Annual Clinical Genetics Meeting